يعرض 1 - 10 نتائج من 361 نتيجة بحث عن '"CRUCIANI, M"', وقت الاستعلام: 0.95s تنقيح النتائج
  1. 1
    دورية أكاديمية
  2. 2
    دورية أكاديمية
  3. 3
    دورية أكاديمية
  4. 4
    دورية أكاديمية

    المساهمون: Université de Lille, CNRS, Service de parasitologie et mycologie CHRU de Besançon, Laboratoire Chrono-environnement (UMR 6249) LCE, Università degli Studi di Padova = University of Padua Unipd, Université Paris Cité UPCité, Centre National de Référence Mycoses Invasives et Antifongiques - National Reference Center Invasive Mycoses & Antifungals CNRMA, Hôpitaux Universitaire Saint-Louis, Lariboisière, Fernand-Widal, Mycologie moléculaire - Molecular Mycology, CHU Henri Mondor Créteil, École nationale vétérinaire d'Alfort ENVA, Université Paris-Est Créteil Val-de-Marne - Faculté de médecine UPEC Médecine, Biologie et Pathogénicité fongiques BPF, Hôpital Necker - Enfants Malades AP-HP, Mycologie moléculaire, Università degli Studi di Milano = University of Milan UNIMI, Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576 UGSF, Laboratoire de parasitologie mycologie (CHU de Dijon), Laboratoire de parasitologie et de mycologie médicales CHU Amiens, Laboratoire de Parasitologie et de Mycologie Médicale Strasbourg, Leopold Franzens Universität Innsbruck - University of Innsbruck, UFR Médecine Santé - Université Paris Cité UFR Médecine UPCité, University Medical Center Utrecht, Universiteit Utrecht / Utrecht University Utrecht, Statens Serum Institut Copenhagen, Centre de Physiopathologie Toulouse Purpan CPTP, Service de Parasitologie et Mycologie CHU Toulouse, Erasmus University Medical Center Rotterdam Erasmus MC, Innsbruck Medical University = Medizinische Universität Innsbruck IMU, University Hospital Brno, Centre Hospitalier Universitaire Strasbourg CHU Strasbourg, Centre Hospitalier Universitaire de Nantes CHU Nantes, CHU Clermont-Ferrand, University Hospital Wuerzburg / Universitäts­klinikum Würzburg, Medizinische Universität Wien = Medical University of Vienna, University Hospital of Wales UHW, University of Texas Health Science Center at San Antonio San Antonio, Tx, USA

    الوصف: Interlaboratory evaluations of Mucorales qPCR assays were developed to assess the reproducibility and performance of methods currently used. The participants comprised 12 laboratories from French university hospitals (nine of them participating in the Modimucor study) and 11 laboratories participating in the Fungal PCR Initiative. For panel 1, three sera were each spiked with DNA from three different species (Rhizomucor pusillus, Lichtheimia corymbifera, Rhizopus oryzae). For panel 2, six sera with three concentrations of R. pusillus and L. corymbifera (1, 10, and 100 genomes/ml) were prepared. Each panel included a blind negative-control serum. A form was distributed with each panel to collect results and required technical information, including DNA extraction method, sample volume used, DNA elution volume, qPCR method, qPCR template input volume, qPCR total reaction volume, qPCR platform, and qPCR reagents used. For panel 1, assessing 18 different protocols, qualitative results (positive or negative) were correct in 97% of cases (70/72). A very low interlaboratory variability in Cq values (SD = 1.89 cycles) were observed. For panel 2 assessing 26 different protocols, the detection rates were high (77–100%) for 5/6 of spiked serum. There was a significant association between the qPCR platform and performance. However, certain technical steps and optimal combinations of factors may also impact performance. The good reproducibility and performance demonstrated in this study support the use of Mucorales qPCR as part of the diagnostic strategy for mucormycosis. ; 59;2

    وصف الملف: application/octet-stream

    العلاقة: Medical Mycology; http://hdl.handle.net/20.500.12210/111765Test

  5. 5
    دورية أكاديمية
  6. 6
    دورية أكاديمية

    المساهمون: Bigi, S., Ganfi, V., Borelli, E., Potenza, L., Artioli, F., Eliardo, S., Mucciarini, C., Cottafavi, L., Ferrari, U., Lombardo, L., Cagossi, K., Pietramaggiori, A., Fantuzzi, V., Bernardini, I., Cruciani, M., Cacciari, C., Odejide, O., Adolfo Porro, C., Zimmermann, C., Efficace, F., Bruera, E., Luppi, M., Bandieri, E.

    الوصف: BACKGROUND: Oncologists are often concerned that talking about death with patients may hinder their relationship. However, the views of death held by patients have not been thoroughly investigated. This study aimed to describe the perception of death among patients with advanced cancer receiving early palliative care (EPC) and their caregivers. MATERIAL AND METHODS: Qualitative and quantitative analyses were performed on 2 databases: (a) transcripts of open-ended questionnaires administered to 130 cancer patients receiving EPC with a mean age of 68.4 years and to 115 primary caregivers of patients on EPC with a mean age of 56.8; (b) texts collected from an Italian forum, containing instances of web-mediated interactions between patients and their caregivers. RESULTS: Quantitative analysis shows that: (a) patients and caregivers are not afraid of speaking about death; (b) patients and caregivers on EPC use the word "death" significantly more than patients on standard oncology care (SOC) and their caregivers (P < .0001). For both participants on EPC and SOC, the adjectives and verbs associated with the word "death" have positive connotations; however, these associations are significantly more frequent for participants on EPC (verbs, Ps < .0001; adjectives, Ps < .003). Qualitative analysis reveals that these positive connotations refer to an actual, positive experience of the end of life in the EPC group and a wish or a negated event in the SOC group. CONCLUSIONS: EPC interventions, along with proper physician-patient communication, may be associated with an increased acceptance of death in patients with advanced cancer and their caregivers.

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36320128; info:eu-repo/semantics/altIdentifier/wos/WOS:000877747400001; volume:28; issue:1; firstpage:54; lastpage:62; journal:THE ONCOLOGIST; https://hdl.handle.net/11380/1296808Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85146531943

  7. 7
    دورية أكاديمية
  8. 8
    دورية أكاديمية

    المساهمون: Etna, M. P., Severa, M., Licursi, V., Pardini, M., Cruciani, M., Rizzo, F., Giacomini, E., Macchia, G., Palumbo, O., Stallone, R., Carella, M., Livingstone, M., Negri, R., Pellegrini, S., Coccia, E. M.

    الوصف: In human primary dendritic cells (DC) rapamycin—an autophagy inducer and protein synthesis inhibitor—overcomes the autophagy block induced by Mycobacterium tuberculosis (Mtb) and promotes a Th1 response via IL-12 secretion. Here, the immunostimulatory activity of rapamycin in Mtb-infected DC was further investigated by analyzing both transcriptome and translatome gene profiles. Hundreds of differentially expressed genes (DEGs) were identified by transcriptome and translatome analyses of Mtb-infected DC, and some of these genes were found further modulated by rapamycin. The majority of transcriptome-associated DEGs overlapped with those present in the translatome, suggesting that transcriptionally stimulated mRNAs are also actively translated. In silico analysis of DEGs revealed significant changes in intracellular cascades related to cytokine production, cytokine-induced signaling and immune response to pathogens. In particular, rapamycin treatment of Mtb-infected DC caused an enrichment of IFN-β, IFN-λ and IFN-stimulated gene transcripts in the polysome-associated RNA fraction. In addition, rapamycin led to an increase of IL-12, IL-23, IL-1β, IL-6, and TNF-α but to a reduction of IL-10. Interestingly, upon silencing or pharmacological inhibition of GSK-3β, the rapamycin-driven modulation of the pro- and anti-inflammatory cytokine balance was lost, indicating that, in Mtb-infected DC, GSK-3β acts as molecular switch for the regulation of the cytokine milieu. In conclusion, our study sheds light on the molecular mechanism by which autophagy induction contributes to DC activation during Mtb infection and points to rapamycin and GSK-3β modulators as promising compounds for host-directed therapy in the control of Mtb infection.

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33936070; info:eu-repo/semantics/altIdentifier/wos/WOS:000645669000001; volume:12; firstpage:1; lastpage:16; numberofpages:16; journal:FRONTIERS IN IMMUNOLOGY; http://hdl.handle.net/11573/1550695Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85105228964

  9. 9
    دورية أكاديمية

    المساهمون: Rubino, E., Cruciani, M., Tchitchek, N., Le Tortorec, A., Rolland, A. D., Veli, O., Vallet, L., Gaggi, G., Michel, F., Dejucq-Rainsford, N., Pellegrini, S.

    الوصف: Ubiquitin-specific peptidase 18 (USP18) acts as gatekeeper of type I interferon (IFN) responses by binding to the IFN receptor subunit IFNAR2 and preventing activation of the downstream JAK/STAT pathway. In any given cell type, the level of USP18 is a key determinant of the output of IFN-stimulated transcripts. How the baseline level of USP18 is finely tuned in different cell types remains ill defined. Here, we identified microRNAs (miRNAs) that efficiently target USP18 through binding to the 3’untranslated region (3’UTR). Among these, three miRNAs are particularly enriched in circulating monocytes which exhibit low baseline USP18. Intriguingly, the USP18 3’UTR sequence is duplicated in human and chimpanzee genomes. In humans, four USP18 3’UTR copies were previously found to be embedded in long intergenic non-coding (linc) RNA genes residing in chr22q11.21 and known as FAM247A-D. Here, we further characterized their sequence and measured their expression profile in human tissues. Importantly, we describe an additional lincRNA bearing USP18 3’UTR (here linc-UR-B1) that is expressed only in testis. RNA-seq data analyses from testicular cell subsets revealed a positive correlation between linc-UR-B1 and USP18 expression in spermatocytes and spermatids. Overall, our findings uncover a set of miRNAs and lincRNAs, which may be part of a network evolved to fine-tune baseline USP18, particularly in cell types where IFN responsiveness needs to be tightly controlled.

    وصف الملف: ELETTRONICO

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33633774; info:eu-repo/semantics/altIdentifier/wos/WOS:000618640600001; volume:11; firstpage:627007; journal:FRONTIERS IN GENETICS; http://hdl.handle.net/11564/764759Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85101234751; https://www.frontiersin.org/articles/10.3389/fgene.2020.627007/fullTest

  10. 10
    دورية أكاديمية

    المصدر: Rocchi , S , Scherer , E , Mengoli , C , Alanio , A , Botterel , F , Bougnoux , M E , Bretagne , S , Cogliati , M , Cornu , M , Dalle , F , Damiani , C , Denis , J , Fuchs , S , Gits-Muselli , M , Hagen , F , Halliday , C , Hare , R , Iriart , X , Klaassen , C , Lackner , M , Lengerova , M , Letscher-Bru , V , Morio , F , Nourrisson , C , Posch , ....

    الوصف: Interlaboratory evaluations of Mucorales qPCR assays were developed to assess the reproducibility and performance of methods currently used. The participants comprised 12 laboratories from French university hospitals (nine of them participating in the Modimucor study) and 11 laboratories participating in the Fungal PCR Initiative. For panel 1, three sera were each spiked with DNA from three different species (Rhizomucor pusillus, Lichtheimia corymbifera, Rhizopus oryzae). For panel 2, six sera with three concentrations of R. pusillus and L. corymbifera (1, 10, and 100 genomes/ml) were prepared. Each panel included a blind negative-control serum. A form was distributed with each panel to collect results and required technical information, including DNA extraction method, sample volume used, DNA elution volume, qPCR method, qPCR template input volume, qPCR total reaction volume, qPCR platform, and qPCR reagents used. For panel 1, assessing 18 different protocols, qualitative results (positive or negative) were correct in 97% of cases (70/72). A very low interlaboratory variability in Cq values (SD = 1.89 cycles) were observed. For panel 2 assessing 26 different protocols, the detection rates were high (77-100%) for 5/6 of spiked serum. There was a significant association between the qPCR platform and performance. However, certain technical steps and optimal combinations of factors may also impact performance. The good reproducibility and performance demonstrated in this study support the use of Mucorales qPCR as part of the diagnostic strategy for mucormycosis.